Published in

Taylor and Francis Group, OncoImmunology, 1(2), p. e22789, 2013

DOI: 10.4161/onci.22789

Taylor and Francis Group, OncoImmunology, 1(1), p. 28-37, 2012

DOI: 10.4161/onci.1.1.17938

Links

Tools

Export citation

Search in Google Scholar

Trial Watch: Monoclonal antibodies in cancer therapy

Journal article published in 2012 by Erika Vacchelli, Alexander Eggermont, Lorenzo Galluzzi, Wolf Hervé Fridman, Jerome Galon, Catherine Sautès-Fridman, Jessica Zucman-Rossi ORCID, Eric Tartour, Laurence Zitvogel, Guido Kroemer
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

During the past 20 years, dozens-if not hundreds-of monoclonal antibodies have been developed and characterized for their capacity to mediate antineoplastic effects, either as they activate/enhance tumor-specific immune responses, either as they interrupt cancer cell-intrinsic signal transduction cascades, either as they specifically delivery toxins to malignant cells or as they block the tumor-stroma interaction. Such an intense research effort has lead to the approval by FDA of no less than 14 distinct molecules for use in humans affected by hematological or solid malignancies. In the inaugural issue of OncoImmunology, we briefly described the scientific rationale behind the use of monoclonal antibodies in cancer therapy and discussed recent, ongoing clinical studies investigating the safety and efficacy of this approach in patients. Here, we summarize the latest developments in this exciting area of clinical research, focusing on high impact studies that have been published during the last 15 months and clinical trials launched in the same period to investigate the therapeutic profile of promising, yet hitherto investigational, monoclonal antibodies.